GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Frequency Therapeutics Inc (NAS:FREQ) » Definitions » 14-Day RSI

Frequency Therapeutics (Frequency Therapeutics) 14-Day RSI : 51.70 (As of May. 07, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Frequency Therapeutics 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-05-07), Frequency Therapeutics's 14-Day RSI is 51.70.

The industry rank for Frequency Therapeutics's 14-Day RSI or its related term are showing as below:

FREQ's 14-Day RSI is not ranked
in the Biotechnology industry.
Industry Median: 48.93 vs FREQ: 51.70

Competitive Comparison of Frequency Therapeutics's 14-Day RSI

For the Biotechnology subindustry, Frequency Therapeutics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Frequency Therapeutics's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Frequency Therapeutics's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Frequency Therapeutics's 14-Day RSI falls into.



Frequency Therapeutics  (NAS:FREQ) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Frequency Therapeutics  (NAS:FREQ) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Frequency Therapeutics 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Frequency Therapeutics's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Frequency Therapeutics (Frequency Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
75 Hayden Avenue, Suite 300, Lexington, MA, USA, 02421
Frequency Therapeutics Inc is a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by degenerative diseases. Its Progenitor Cell Activation approach uses combinations of molecules to activate progenitor cells within the body to create functional tissue. Its product candidate FX-322 is being developed for treating sensorineural hearing loss.
Executives
Richard J. Mitrano officer: VP Finance & Operations C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
David L. Lucchino director, officer: President and CEO C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Christopher R. Loose officer: Chief Scientific Officer C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Quentin Mccubbin officer: Chief Manufacturing Officer C/O FREQUENCY THERAPEUTICS, INC., 10 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Wendy S Arnold officer: Chief People Officer 19 PRESIDENTIAL WAY, SUITE 203, WOBURN MA 01801
Carl Lebel officer: Chief Development Officer 23256 MARIPOSA DE ORO, MALIBU CA 90265
Peter P. Pfreundschuh officer: Chief Financial Officer C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Michael Bookman officer: General Counsel and Secretary C/O FREQUENCY THERAPEUTICS, INC., 10 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Joel S Marcus director, 10 percent owner C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Cynthia L Feldmann director 17 WINTHROP ROAD, WAYLAND MA 01778
Marc A Cohen director 1000 WILSON BLVD. #1800, ARLINGTON VA 22209
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Partners, L.p. 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Robert Langer director 98 MONTVALE RD, NEWTON MA 02459
Alexandria Venture Investments, Llc 10 percent owner 26 NORTH EUCLID AVENUE, PASADENA CA 91101

Frequency Therapeutics (Frequency Therapeutics) Headlines